Adial Pharmaceuticals Return on Equity

Adial Pharmaceuticals (ADIL) currently reports a ROE of 150.61%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore Adial Pharmaceuticals's ROE history and peer comparisons.

Adial Pharmaceuticals's ROE of 150.61% is higher than the Healthcare sector average of 21.67%. That is roughly 595.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Adial Pharmaceuticals's current 150.61% should be judged against Healthcare norms (sector average: 21.67%) and against ADIL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 150.61%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Adial Pharmaceuticals, and consider following ADIL for alerts when major investors trade the stock.

Adial Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 150.61% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADIL with unrelated industries.